Multiple myeloma trials in China

In China 203 Also abroad 703

203 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Not yet taking people in China
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
Where
Nanjing
Age
18 years and over
People
27
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07113496
Phase 1Not yet taking people in China
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
Where
Tianjin
Age
18 years and over
People
19
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07114432
Phase 1/2Taking people
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Where
Tianjin
Age
18 years to 70 years
People
50
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07109323
Phase 2Taking people
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Where
Tianjin
Age
18 years and over
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07106671
Phase 2Taking people
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
Where
Tianjin
Age
18 years to 70 years
People
80
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06793449
Phase 2Taking people
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
Where
Tianjin
Age
18 years to 75 years
People
40
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06880393
Phase 1/2Not yet taking people in China
A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
Where
Shanghai, Xi’an
Age
18 years and over
People
32
Run by
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
See details and how to joinNCT07090954
Early phase 1Taking people
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
Where
Hefei
Age
19 years to 75 years
People
36
Run by
Anhui Provincial Hospital
See details and how to joinNCT07085559
Phase 3Not yet taking people in China
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Where
Wuhan
Age
18 years to 90 years
People
530
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06580223
Early phase 1Taking people
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
Where
Zhenjiang
Age
18 years and over
People
21
Run by
YANRU WANG
See details and how to joinNCT06976437
No phaseNot yet taking people in China
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
Where
Xuzhou
Age
18 years to 70 years
People
20
Run by
The Affiliated Hospital of Xuzhou Medical University
See details and how to joinNCT07034755
No phaseTaking people
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Where
Taiyuan
Age
14 years to 75 years
People
50
Run by
Hebei Senlang Biotechnology Inc., Ltd.
See details and how to joinNCT05618041
Phase 1/2Taking people
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
Where
Beijing
Age
21 years to 90 years
People
60
Run by
Essen Biotech
See details and how to joinNCT07032129
No phaseTaking people
Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
Where
Beijing, Tianjin, Wuhan, Zhengzhou
People
1,500
Run by
Nanjing IASO Biotechnology Co., Ltd.
See details and how to joinNCT07028970
Phase 4Taking people
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Where
Suzhou
Age
18 years and over
People
59
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT06409702
Phase 1Taking people
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Where
Wuhan
Age
18 years to 75 years
People
18
Run by
Chunrui Li
See details and how to joinNCT05219721
Early phase 1Taking people
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
Where
Beijing
Age
18 years to 80 years
People
50
Run by
Peking University First Hospital
See details and how to joinNCT06717113
Early phase 1Taking people
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
Where
Nanchang
Age
18 years to 75 years
People
12
Run by
The First Affiliated Hospital of Nanchang University
See details and how to joinNCT06999031
No phaseTaking people
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
Where
Hefei
Age
3 years and over
People
18
Run by
Anhui Provincial Hospital
See details and how to joinNCT06961669
No phaseTaking people
The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
Where
Wuhan
Age
18 years to 80 years
People
458
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06228794
Phase 1Taking people
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Where
Shanghai
Age
18 years to 75 years
People
12
Run by
Nanjing IASO Biotechnology Co., Ltd.
See details and how to joinNCT05759793
Phase 2Taking people
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Where
Beijing, Hefei, Jinan, Tianjin, Zhengzhou
Age
18 years to 65 years
People
120
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT05294055
Phase 2Not yet taking people in China
Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
Where
Xuzhou
Age
18 years to 70 years
People
60
Run by
Xuzhou Medical University
See details and how to joinNCT06963866
Phase 2Taking people
GR1803 Injection in Patients With RRMM
Where
Tianjin
Age
18 years and over
People
30
Run by
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
See details and how to joinNCT06952075
Phase 2Taking people
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Where
Wuhan
Age
18 years to 70 years
People
54
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06140966